AVB-08
Schizophrenia and Psychosis (including dementia-related)
Pre-clinicalActive
Key Facts
Indication
Schizophrenia and Psychosis (including dementia-related)
Phase
Pre-clinical
Status
Active
Company
About Aivo Biosciences
Aivo Biosciences is a private, preclinical biotech leveraging deep expertise in muscarinic receptor pharmacology to develop novel CNS drugs. Its lead candidate, AVB-08, is a highly potent and selective M1 agonist optimized for brain penetration and once-daily dosing, targeting a large market opportunity in schizophrenia and dementia-related psychosis. The company is led by a seasoned team with a track record in muscarinic drug development and biotech operations, aiming for rapid clinical proof-of-concept.
View full company profile